• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

August 24, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Algernon Pharmaceuticals NP-120 (Ifenprodil) hospitalized patients with confirmed COVID-19 first patient enrolled in the U.S. in phase 2b/3 trial
Enzychem LifeSciences EC-18 patients with acute respiratory distress syndrome (ARDS) due to COVID-19 pneumonia IND approved by the FDA for phase 2 trial
Accelerate Diagnostics BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully automated MS-Fast instrument COVID-19 antibody test Emergency Use Authorization (EUA) granted by the FDA
LumiraDx LumiraDx SARS-CoV-2 antigen test detection of SARS-CoV-2 antigens EUA granted by the FDA
Other Trials and Actions
CARsgen Therapeutics CT041 claudin18.2-positive solid tumors IND approved by the FDA
Acepodia ACE1702 HER2-expressing solid tumors first patients dosed in phase 1 trial
Arrowhead Pharmaceuticals ARO-HIF2 clear-cell renal cell carcinoma first patients dosed in phase 1b trial
Enterprise Therapeutics ETD002 all cystic fibrosis patients, independent of genotype first patients dosed in phase 1 trial
Epirium Bio EPM-01 Becker muscular dystrophy enrollment of first patients in phase 1 trial
Immunic IMU-856 diarrhea-predominant irritable bowel syndrome (IBS-D), ulcerative colitis (UC) and Crohn's disease dosing of first patients in phase 1 trial
I-Mab plonmarlimab (TJM2) rheumatoid arthritis dosing of first patient in phase 1b trial
Pluristem Therapeutics PLX-R18 incomplete hematopoietic recovery following hematopoietic cell transplantation patient enrollment complete in phase 1 trial
Ultimovacs ASA UV1 in combination with pembrolizumab metastatic malignant melanoma patient enrollment complete in phase 1 trial
4D Molecular Therapeutics 4D-125 X-linked retinitis pigmentosa initiation of phase 1/2 trial
Trefoil Therapeutics TTHX1114 regenerative treatment of corneal endothelial dystrophies initiation of phase 1/2 trial
Alkermes ALKS 4230 advanced, malignant solid tumors initiation of phase 2 trial
Amplyx MAU868 BK viremia in kidney transplant recipients dosing of first patient in phase 2 trial
Ascletis Pharma ASC22 (Envafolimab) chronic hepatitis B dosing of first patient in phase 2a trial
AzurRx MS1819 cystic fibrosis patients with exocrine pancreatic insufficiency dosing of first patients in phase 2b trial
Imara IMR-687 adult patients with sickle cell disease dosing of first patient in phase 2b trial
Neuroptika NRO-1 dry eye disease patient enrollment complete in phase 2 trial
Verona Pharma pressurized metered-dose inhaler (pMDI) formulation of ensifentrine moderate to severe chronic obstructive pulmonary disease initiation of phase 2 trial
BioLineRx motixafortide (BL-8040) mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma patient enrollment complete in phase 2 trial
Endospan NEXUS Aortic Arch Stent Graft System thoracic aortic arch disease IDE approved by the FDA
4D Molecular Therapeutics 4D-310 Fabry Disease Fast Track designation granted by the FDA
Akeso Biopharma AK104 patients with recurrent or metastatic squamous cervical cancer who have disease progression on or after platinum-based chemotherapy Fast Track designation granted by the FDA
Precision Biosciences PBCAR0191 advanced B-cell precursor acute lymphoblastic leukemia Fast Track designation granted by the FDA
Mustang Bio MB-107 X-linked severe combined immunodeficiency in newly diagnosed infants Rare Pediatric Disease designation granted by the FDA
Scholar Rock SRK-015 spinal muscular atrophy Rare Pediatric Disease designation granted by the FDA
Genentech Enspryng (satralizumab-mwge) adults with AQP4 antibody-positive neuromyelitis optica spectrum disorder approved by the FDA
RapidAI Rapid LVO detecting suspected large vessel occlusions approved by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing